TScan Therapeutics Files 2023 Annual Report Amendment

TL;DR

TScan Therapeutics filed an amendment to its 2023 10-K on April 10, 2024.

AI Summary

TScan Therapeutics, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2023. The company, incorporated in Delaware and headquartered in Waltham, MA, is involved in the biological products sector. This filing provides updated information for the period ending December 31, 2023, with the amendment filed on April 10, 2024.

Why It Matters

This amendment to the annual report provides updated financial and operational information for TScan Therapeutics, Inc., which is crucial for investors to assess the company's performance and outlook.

Risk Assessment

Risk Level: low — This filing is an amendment to a standard annual report, not indicating new material risks.

Key Numbers

• 2023 — Fiscal Year End (The annual report covers the fiscal year ending December 31, 2023.)
• April 10, 2024 — Amendment Filing Date (This is the date the amendment to the 10-K was filed with the SEC.)

Key Players & Entities

• TScan Therapeutics, Inc. (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• Waltham, Massachusetts (location) — Principal executive office address
• 001-40603 (filing_id) — Commission File Number
• 20231231 (date) — Fiscal year end
• 20240410 (date) — Filing date of amendment

FAQ

From the Filing

0001193125-24-091386.txt : 20240410 0001193125-24-091386.hdr.sgml : 20240410 20240410073037 ACCESSION NUMBER: 0001193125-24-091386 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240410 DATE AS OF CHANGE: 20240410 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TScan Therapeutics, Inc. CENTRAL INDEX KEY: 0001783328 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 825282075 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-40603 FILM NUMBER: 24834256 BUSINESS ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 857-399-9500 MAIL ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 10-K/A 1 d818033d10ka.htm 10-K/A 10-K/A true FY 0001783328 Yes Yes No No 0001783328 2023-01-01 2023-12-31 0001783328 2023-06-30 0001783328 tcrx:VotingCommonStockMember 2024-04-09 0001783328 us-gaap:NonvotingCommonStockMember 2024-04-09 iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 10-K/A (Amendment No. 1)     (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2023 OR   ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM     TO      Commission File Number 001-40603     TScan Therapeutics, Inc. (Exact name of Registrant as specified in its Charter)       Delaware   82-5282075 (State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.) 830 Winter Street Waltham , Massachusetts   02451 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: ( 857 ) 399-9500 Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Voting Common Stock, $0.0001 par value per share   TCRX   The Nasdaq Global Market, LLC Securities registered pursuant to Section 12(g) of the Act: None     Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES ☐  NO  ☒ Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YES ☐  NO  ☒ Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  YES  ☒ NO ☐ Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  YES  ☒ NO ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.   Large accelerated fil